<unk>  (previously known as E5555) is a potent and orally-active PAR-1 inhibitor that was developed by Eisai. Compared with vorapaxar,<unk>  is a synthetic agent with a shorter elimination half-life and a primary gastrointestinal metabolism. This small molecule inhibits the binding of thrombin either at or very close to the tethered ligand-binding site and available evidence indicates that<unk>  may have potential anti-inflammatory properties. The drug is currently not commercially available.
Atopaxar
Vorapaxar
Etamivan
Tasimelteon
Patiromer
Pleconaril
Zaleplon
Fosaprepitant